cGAS regulators and their uses
By developing cGAS modulators with I to If structures, the disease problem caused by excessive cGAS activity in existing technologies has been solved, achieving specific inhibition of cGAS and effective treatment of various diseases.
Patent Information
- Application Number
- CN202510625322.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-15
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies are insufficient to effectively inhibit the excessive activity of cGAS, leading to diseases caused by inappropriate type I interferon activity, and there is a lack of specific small molecule inhibitors and degrading agents.
A specific class of compounds, cGAS modulators with structures of formulas I to If, have been developed, including small molecule-antibody conjugates, small molecule-peptide conjugates, and bifunctional protein degraders, for the direct inhibition or regulation of cGAS activity.
These compounds can effectively inhibit cGAS activity and reduce inappropriate type I interferon activity, and can be used to prevent and treat a variety of cGAS-related diseases, such as inflammation, autoimmune diseases and cancer.
Smart Images

Figure CN123106675A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of medicinal chemistry, and in particular to cGAS modifiers and their uses. Background Technology
[0002] Cyclic GMP-AMP synthase (cGAS) is a nucleotransferase located in the cytoplasm that recognizes dsDNA originating from pathogens, the nucleus, or mitochondria. cGAS binds to dsDNA, activating GTP and ATP to synthesize cyclic dinucleotide GMP-AMP (cGAMP). Overexpression of cGAS activates the transcription factor IRF3 and induces IFNβ in a STING-dependent manner. cGAS acts as a cytoplasmic DNA sensor, inducing interferon through the production of the second messenger cGAMP. The crucial role of cGAS in cytoplasmic DNA sensing has been demonstrated in various pathogenic bacteria, viruses, and retroviruses. cGAS-specific small molecule inhibitors and degraders are of significant value in treating diseases caused by inappropriate cGAS activity and the resulting unwanted type I interferon activity. Summary of the Invention
[0003] In view of this, according to one aspect, the present invention provides compounds of Formula I, or pharmaceutically acceptable stereoisomers, solvates, hydrates, prodrugs, stable isotope derivatives, and salts:
[0004]
[0005] Among them, R1, R2, R3, and R5 are each independently selected from hydrogen, halogen, cyano, hydroxyl, amino, alkyl, alkoxy, haloalkyl, and cycloalkyl.
[0006] R4 is selected from hydrogen, alkyl, alkoxy, haloalkyl, cycloalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic; wherein when the heteroaryl, aryl and heterocyclic are substituted, the substituent is selected from halogen, amino, cyano, C1-C4 alkyl and C1-C4 alkoxy.
[0007] R6 is selected from -CH2-Ra, substituted or unsubstituted heteroaryl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group; wherein when the heteroaryl, aryl and heterocyclic group are substituted, the substituent is selected from halogen, amino, cyano, alkyl, alkoxy, haloalkyl, cycloalkyl, -O(CH2). p OH; p is 1, 2 or 3; Ra is selected from cyano, hydroxyl, amino, alkyl and alkoxy groups;
[0008] n is 0, 1, or 2; and
[0009] m can be 0, 1, or 2.
[0010] In some embodiments, R1, R2, R3, and R5 are each independently selected from hydrogen, halogen, cyano, hydroxyl, amino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, and C3-C6 cycloalkyl.
[0011] R4 is selected from hydrogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C3-C6 cycloalkyl, substituted or unsubstituted 5-8-membered heteroaryl, substituted or unsubstituted 6-8-membered aryl, substituted or unsubstituted 4-8-membered heterocyclic group; wherein when the heteroaryl, aryl and heterocyclic group are substituted, the substituent is selected from halogen, amino, cyano, C1-C4 alkyl and C1-C4 alkoxy;
[0012] R6 is selected from -CH2-Ra, substituted or unsubstituted 5-8-membered heteroaryl, substituted or unsubstituted 6-8-membered aryl, substituted or unsubstituted 4-8-membered heterocyclic group; wherein when the heteroaryl, aryl and heterocyclic group are substituted, the substituent is selected from halogen, amino, cyano, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C3-C6 cycloalkyl, -O(CH2)pOH; p is 1, 2 or 3; Ra is selected from cyano, hydroxyl, amino, C1-C4 alkyl, C1-C4 alkoxy.
[0013] In some embodiments, the compound may have the structure shown in Formula Ia:
[0014]
[0015] R1, R2, R3, R4, R5, and R6 are defined as described above.
[0016] In some embodiments, the compound may have the structure shown in Formula Ib:
[0017]
[0018] R1, R2, R3, R4, R5, and R6 are defined as described above.
[0019] In some embodiments, the compound may have the structure shown in Formula Ic:
[0020]
[0021] R1, R2, R3, R4, R5, and R6 are defined as described above.
[0022] In some embodiments, the compound may have the structure shown in Formula Id:
[0023]
[0024] R1, R2, R3, R4, R5, and R6 are defined as described above.
[0025] In some embodiments, the compound may have the structure shown in Formula Ie:
[0026]
[0027] R1, R2, R3, R4, R5, and R6 are defined as described above.
[0028] In some embodiments, the compound may have the structure shown in Formula If:
[0029]
[0030] R1, R2, R3, R4, R5, and R6 are defined as described above.
[0031] In some embodiments, R1, R2, R3, and R5 are each independently selected from hydrogen, halogens, and C1-C4 alkyl groups;
[0032] R4 is selected from hydrogen, substituted or unsubstituted 5-8 membered heteroaryl groups; wherein when the heteroaryl group is substituted, the substituent is selected from amino or C1-C4 alkyl groups;
[0033] R6 is selected from -CH2-Ra, or substituted or unsubstituted 5-8 membered heteroaryl groups; wherein when the heteroaryl group is substituted, the substituent is selected from C1-C4 alkoxy or -O(CH2)pOH; p is 1, 2 or 3; Ra is selected from hydroxyl, amino or C1-C4 alkoxy.
[0034] In some implementations, R1 and R2 are independently selected from halogens, especially chlorine.
[0035] In some embodiments, R3 and R5 are each independently selected from hydrogen or C1-C4 alkyl (e.g., methyl).
[0036] In some embodiments, R4 is selected from hydrogen, substituted or unsubstituted 5-6 membered heteroaryl (e.g., pyrazolyl or pyridinyl); wherein when the heteroaryl is substituted, the substituent is selected from amino or C1-C4 alkyl (e.g., methyl).
[0037] In some embodiments, R6 is selected from -CH2-Ra, or a substituted or unsubstituted 6-membered heteroaryl group (e.g., pyrimidinyl); wherein when the heteroaryl group is substituted, the substituent is selected from C1-C4 alkoxy or -O(CH2)2OH; Ra is selected from hydroxyl, amino or C1-C4 alkoxy (e.g., methoxy).
[0038] In some embodiments, the present invention relates to compounds selected from, or pharmaceutically acceptable stereoisomers, solvates, hydrates, prodrugs, stable isotope derivatives, and salts:
[0039]
[0040]
[0041]
[0042]
[0043] In a second aspect, the present invention provides small molecule-antibody conjugates or small molecule-peptide conjugates based on the compounds of the present invention. In other aspects, the present invention also relates to bifunctional protein degraders or other bifunctional small molecule drugs based on the compounds of the present invention.
[0044] In a third aspect, the present invention provides pharmaceutical compositions comprising the compounds of the present invention or pharmaceutically acceptable stereoisomers thereof, solvates, hydrates, prodrugs, stable isotope derivatives and salts thereof, or small molecule-antibody conjugates, small molecule-peptide conjugates, bifunctional protein degraders or other bifunctional small molecule drugs of the compounds of the present invention; and pharmaceutically acceptable carriers.
[0045] In some embodiments, a pharmaceutically acceptable carrier may include excipients, diluents, or surfactants.
[0046] In some embodiments, pharmaceutically acceptable excipients include one or more of binders, fillers, disintegrants, lubricants, and flow aids.
[0047] Furthermore, pharmaceutically acceptable carriers include one or more of creams, emulsions, gels, liposomes, and nanoparticles.
[0048] Fourthly, the present invention provides the use of the compounds, small molecule-antibody conjugates, small molecule-peptide conjugates, bifunctional protein degraders or other bifunctional small molecule drugs or pharmaceutical compositions defined herein in the preparation of medicaments for the prevention and / or treatment of cGAS-related diseases.
[0049] In some implementations, cGAS-related diseases include inflammation, autoimmune diseases, cancer, infections, central nervous system diseases or disorders, metabolic diseases, cardiovascular diseases, respiratory diseases, kidney diseases, liver diseases, eye diseases, skin diseases, lymphatic diseases, rheumatic diseases, graft-versus-host disease, and abnormal pain.
[0050] Fourthly, the present invention also provides a method for treating, preventing, and / or treating cGAS-related diseases, comprising administering to a subject in need a therapeutically effective amount of a compound defined in the present invention, a small molecule-antibody conjugate, a small molecule-peptide conjugate, a bifunctional protein degrader, or other bifunctional small molecule drug or pharmaceutical composition.
[0051] The compounds provided by this invention, or their pharmaceutically acceptable stereoisomers, solvates, hydrates, prodrugs, stable isotope derivatives and salts, small molecule-antibody conjugates, small molecule-peptide conjugates, bifunctional protein degraders or other bifunctional small molecule drugs or pharmaceutical compositions, can be used to prepare drugs for treating, inhibiting or preventing cGAS-related diseases or conditions. Detailed Implementation
[0052] To make the technical solution and beneficial effects of the present invention more apparent and understandable, a detailed description is provided below by listing specific embodiments. Unless otherwise defined, the technical and scientific terms used herein have the same meanings as those in the technical field to which this application pertains.
[0053] When used in conjunction with the term "comprising" in the claims and / or specification, the word "a" can mean "one," but it is also known to mean "one or more," "at least one," and "one or more." Similarly, the word "another" can mean at least a second or more.
[0054] As used in this specification and claims, the words “comprising” (and any form of inclusion, such as “comprising” and “including”), “having” (and any form of having, “having,” “including,” and “containing”) are inclusive and open-ended and do not exclude additional unlisted elements or processing steps. The terms “about” or “approximately” are used to indicate that the value includes errors introduced by the instruments and methods used in determining the value.
[0055] The terms "substituted" or "having substituents" refer to a parent compound or part having at least one substituent group. The terms "unsubstituted" or "not having substituents" refer to a parent compound or part having no other substituents except for an undetermined valence chemically saturated with hydrogen atoms.
[0056] In some embodiments, as the present invention refers to alkyl, cycloalkyl, alkoxy, amino, heterocyclic, heteroaryl, aryl, it is optionally substituted (e.g., "substituted" or "unsubstituted" alkyl, "substituted" or "unsubstituted" heterocyclic, "substituted" or "unsubstituted" aryl, or "substituted" or "unsubstituted" heteroaryl group).
[0057] Unless otherwise indicated, a “substituted” group has a substituent at one or more substituted positions of the group, and the substituent is either the same or different at each position when substituting more than one position in any given structure.
[0058] As described herein, "substituent" or "substituent group" refers to a group selected from halogens (F, Cl, Br or I), hydroxyl, mercapto, amino, nitro, carbonyl, carboxyl, alkyl, alkoxy, alkylamino, aryl, aryloxy, arylamino, acyl or other organic moieties conventionally used and accepted in organic chemistry.
[0059] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, which is a straight-chain or branched group containing 1 to 12 carbon atoms, preferably containing 1 to 6, and more preferably alkyl containing 1 to 4 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, etc. The alkyl group can be substituted or unsubstituted. When substituted, the substituent can be substituted at any usable connection point. The substituent is preferably one or more of the following groups, independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl, or carboxylic acid ester group.
[0060] The term "alkoxy" refers to -O- (alkyl) and -O- (unsubstituted cycloalkyl), where alkyl is defined as described above. Non-limiting examples of alkoxy groups include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentoxy, and cyclohexoxy. Alkoxy groups can be optionally substituted or unsubstituted; when substituted, the substituent is preferably one or more of the following groups, independently selected from halogens, deuterium, hydroxyl, oxo, nitro, cyano, and C. 1-6 alkyl.
[0061] The term "hydroxyl group" refers to the -OH group.
[0062] The term "halogen" refers to fluorine, chlorine, bromine, or iodine.
[0063] The term "halogenated alkyl" refers to an alkyl group that has been substituted with a halogen, wherein the alkyl group is as defined above.
[0064] The term "cyano" refers to -CN.
[0065] The term "oxo" refers to an =O group. For example, a carbon atom is connected to an oxygen atom by a double bond, forming a ketone or aldehyde group.
[0066] The term "amino" refers to -NH2.
[0067] The terms "cycloalkyl," "alicyclic," "carbocyclic," and their equivalents refer to groups comprising saturated or partially unsaturated carbocyclic rings in monocyclic, spirocyclic (sharing a single atom), or fused (sharing at least one bond) carbocyclic systems having 3 to 6 carbon atoms. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopenten-1-yl, cyclopenten-2-yl, cyclopenten-3-yl, cyclohexyl, cyclohexen-1-yl, and cyclohexen-2-yl. The term cycloalkyl includes both unsubstituted and substituted cycloalkyl groups.
[0068] The terms "aryl" and "aromatic group" refer to an aromatic group having "4n+2" (π) electrons and 6 to 14 ring atoms in a conjugated monocyclic or polycyclic system (fused or unfused), where n is an integer from 1 to 3. Polycyclic systems include at least one aromatic ring. Aryl groups can be directly linked or linked via C1-C3 alkyl groups (also called arylalkyl or aralkyl groups). Examples of aryl groups include, but are not limited to, phenyl, benzyl, phenethyl, 1-phenylethyl, tolyl, naphthyl, biphenyl, terphenyl, indene, benzocyclooctenyl, benzocycloheptenyl, azulel, acenaphthel, fluorenyl, phenanthrene, anthracene, etc. The term aryl includes both unsubstituted and substituted aryl groups. Aryl groups linked by hydrocarbon groups are also called arylalkyl groups.
[0069] The term "heterocyclic alkyl" or "heterocyclic group" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing 3 to 20 ring atoms, wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen, or sulfur; preferably containing 4 to 12 ring atoms, wherein 1 to 4 are heteroatoms; more preferably containing 3 to 7 ring atoms. Non-limiting examples of monocyclic heterocyclic alkyl groups include pyrrolidinyl, imidazoalkyl, tetrahydrofuranyl, tetrahydrothiophenyl, dihydroimidazoyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, etc.
[0070] The term "heteroaryl" refers to a heteroaryl system comprising 1 to 4 heteroatoms and 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur, and nitrogen. The heteroaryl group is preferably 5 to 12-membered, more preferably 5- or 6-membered. Non-limiting examples include: imidazolyl, furanyl, thiophene, thiazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyrroleyl, tetrazolyl, pyridyl, pyrimidinyl, thiadiazole, pyrazinyl, triazolyl, indazole, benzimidazolyl, etc. The heteroaryl ring may be fused to an aryl, heterocyclic, or cycloalkyl ring, wherein the ring attached to the parent structure is the heteroaryl ring. The heteroaryl group may be optionally substituted or unsubstituted.
[0071] The term "pharmaceutical acceptable" means that the drug, pharmaceutical product, inert ingredient, etc., described by the term is suitable for contact with the tissues of humans and lower animals without adverse toxicity, incompatibility, instability, irritation, allergic reactions, etc., and is commensurate with a reasonable benefit / risk ratio.
[0072] The term "pharmaceutically acceptable stereoisomer" refers to isomers resulting from different spatial arrangements of atoms in a molecule. More specifically, isomers arising from the same order of connection of atoms or groups of atoms in a molecule but different spatial arrangements are called stereoisomers, mainly divided into two categories: stereoisomers caused by bond lengths, bond angles, the presence of double bonds, or rings are called configuration stereoisomers. Generally speaking, configuration stereoisomers cannot or are very difficult to interconvert. Stereomers resulting solely from the rotation of single bonds are called conformational stereoisomers, sometimes also called rotamers. When rotation in a rotamer is hindered and cannot occur, it becomes a "stereoisomer." For example, in the biphenyl structure, when there are large and different substituents at the α- and α'- positions, the rotation of the single bond between the two benzene rings cannot rotate freely due to the obstruction between the substituents, thus producing two stereoisomers.
[0073] In the chemical structure of the compounds described in this disclosure, the / bond does not specify a configuration; that is, the / bond can be any configuration. Or simultaneously include Two configurations. Bond Indicates a single configuration, for In the chemical structure of the compounds described in this disclosure, the bonds... No configuration is specified, meaning it can be Z configuration, E configuration, or both configurations.
[0074] Therefore, the compounds of the present invention may contain asymmetric or chiral centers, and thus exist in different stereoisomeric forms. All stereoisomeric forms of the compounds of the present invention and mixtures thereof, including racemic mixtures, constitute a part of the present invention.
[0075] Furthermore, this invention includes all geometric and positional isomers. For example, if the compounds of this invention contain a double bond or a fused ring, then the cis and trans forms, as well as mixtures, are all covered within the scope of this invention. Each compound disclosed herein includes all enantiomers conforming to the general structure of that compound. The compound may be in racemic or enantiomerically pure form, or any other stereochemical form. Measurement results may reflect data collected for the racemic form, the enantiomerically pure form, or any other stereochemical form.
[0076] Mixtures of diastereomers can be separated into their individual diastereomers based on their physicochemical differences using methods well known to those skilled in the art, such as chromatography and / or fractional crystallization. For example, enantiomers can also be separated using a chiral HPLC column. The compounds of the present invention can also exist in different tautomeric forms, and all such forms are included within the scope of the present invention.
[0077] The term "isotope derivative" refers to compounds whose structure differs only in the presence of one or more isotope-enriched atoms. For example, compounds having the structure disclosed herein, using "deuterium" or "tritium" instead of hydrogen, or using... 18 F-fluorine labeling ( 18 F isotopes) can be used instead of fluorine, or... 11 C-, 13 C-, or 14 C-enriched carbon ( 11 C-, 13 C-, or 14 C-carbon labeling; 11 C-, 13 C-, or 14 Compounds in which carbon atoms are replaced by C-isotopes are within the scope of this disclosure. Such compounds can be used as analytical tools or probes in, for example, biological assays, or as in vivo diagnostic imaging tracers for diseases, or as tracers for pharmacodynamic, pharmacokinetic, or receptor studies. The various deuterated forms of compounds disclosed herein refer to compounds in which each available hydrogen atom bonded to a carbon atom can be independently replaced by a deuterium atom. Those skilled in the art can synthesize deuterated forms of compounds by referring to relevant literature. Commercially available deuteration starting materials can be used in the preparation of deuterated forms of compounds, or they can be synthesized using conventional techniques with deuteration reagents, including but not limited to deuterated boranes, trideuterated borane tetrahydrofuran solutions, deuterated lithium aluminum hydride, deuterated iodoethane, and deuterated iodomethane. Deuterated compounds generally retain activity comparable to undeuterated compounds, and better metabolic stability can be achieved when deuterated at certain specific sites, resulting in certain therapeutic advantages.
[0078] The term "pharmaceutically acceptable salt" refers to a salt of a pharmaceutically acceptable compound. An ideal salt of a compound (basic, acidic, or charged functional group) can retain or improve the biological activity and properties of the parent compound as defined in this invention, and is not biologically undesirable. Pharmaceutically acceptable salts can be those mentioned by Berge et al. in "Pharmaceutical Salts", J. Pharm. Sci. 66, 1-19 (1977). Including but not limited to:
[0079] (1) Salts formed by adding acids to basic or positively charged functional groups. Inorganic acids include hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, aminosulfonic acid, nitric acid, phosphoric acid, carbonates, etc. Organic acids include acetic acid, propionic acid, lactic acid, oxalic acid, glycolic acid, neopentanoic acid, tert-butylacetic acid, β-hydroxybutyric acid, valeric acid, hexanoic acid, cyclopentanepropionic acid, pyruvic acid, malonic acid, succinic acid, malic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, cyclohexylamino Sulfonic acid, benzenesulfonic acid, sulfanilic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 3-phenylpropionic acid, laurylsulfonic acid, lauryl sulfate, oleic acid, palmitic acid, stearic acid, lauric acid, pyruvic acid, pantothenic acid, lactobionic acid, alginic acid, galactobionic acid, galacturonic acid, gluconic acid, glucoheponic acid, glutamic acid, naphthoic acid, hydroxynaphthoic acid, salicylic acid, ascorbic acid, stearic acid, mucoconic acid, etc.
[0080] (2) When the parent compound contains an acidic proton or is replaced by a metal ion, a base can be added to obtain a salt. The metal ions include basic metal ions (e.g., lithium, sodium, potassium), alkaline earth metal ions (magnesium, calcium, barium), or other metal ions such as aluminum, zinc, and iron. Organic bases include, but are not limited to, N,N'-dibenzylethylenediamine, ethanolamine, diethanolamine, triethanolamine, aminobutanetriol, N-methylglucosamine, piperazine, chloroprocaine, procaine, choline, and lysine.
[0081] Pharmaceutically acceptable salts can be synthesized from parent compounds containing basic or acidic fragments using conventional chemical methods. Typically, such salts are prepared by reacting a compound (free acid or base) with an equistoichiometric base or acid in water, an organic solvent, or a mixture of both. Salts can be prepared in situ during the final separation or purification of the pharmaceutical preparation, or by reacting a purified compound of the invention in free acid or base form separately with the desired corresponding base or acid and then separating the resulting salt. The term "pharmaceutically acceptable salt" also includes zwitterionic compounds containing cationic groups covalently bonded to anionic groups, which are referred to as "internal salts." The compounds of the present invention include all acids, salts, bases, and other ionic and nonionic forms. For example, if the compound in the present invention is an acid, the salt form of that compound is also included. Similarly, if the compound in the present invention is a salt, the acidic and / or base forms of that compound are also included.
[0082] The term "solvent" refers to the physical combination of a compound of this disclosure with one or more, preferably one to three, solvent molecules, whether organic or inorganic. This physical combination includes hydrogen bonds. In some cases, such as when one or more, preferably one to three, solvent molecules are incorporated into the lattice of a crystalline solid, the solvate will be separated. Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. Solvation methods are well known in the art.
[0083] The term "hydrate" refers to the case where the solvent in the aforementioned term "solvent" is water.
[0084] The present invention also provides pharmaceutical compositions, in one embodiment of which the pharmaceutical composition comprises: a compound disclosed herein or a pharmaceutically acceptable salt or ester or isomer or hydrate thereof, and a pharmaceutically acceptable excipient or carrier or diluent.
[0085] Specifically, pharmaceutically acceptable excipients include one or more of binders, fillers, disintegrants, lubricants, and flow aids. Pharmaceutically acceptable carriers or diluents include one or more of creams, emulsions, gels, liposomes, and nanoparticles.
[0086] "Pharmaceutical composition" means comprising compounds as described herein, and at least one component depending on the requirements of the route of administration and dosage form, including pharmaceutically acceptable carriers, diluents, adjuvants, excipients, or loads, such as preservatives, fillers, disintegrants, wetting agents, emulsifiers, suspending agents, sweeteners, flavoring agents, aromatizers, antimicrobial agents, antifungal agents, lubricants, and dispersants. "Prevention" or "protection" is used to indicate at least a reduction in the likelihood of acquiring a disease or condition (or susceptibility) or developing a disease or disorder (i.e., preventing the development of clinical symptoms of at least one disease in patients who may be exposed to or susceptible to the disease but have not yet experienced or displayed symptoms of the disease).
[0087] In some embodiments, “treating” any disease or condition means alleviating at least one disease or condition. In some embodiments, “treating” means alleviating at least one bodily parameter, which may be identifiable or indistinguishable to the patient. In some embodiments, “treating” means suppressing a disease or condition physically (e.g., stabilization of identifiable symptoms) or physiologically (e.g., stabilization of bodily parameters) or both. In some embodiments, “treating” means improving quality of life or a side effect of a disease in a subject in need. A “therapeutic effective amount” means an amount of compound administered to a subject for the treatment or prevention of a disease sufficient to achieve the effect of treating or preventing the disease. A “therapeutic effective amount” will vary depending on the compound; the disease and its severity; the age, weight, etc., of the subject being treated or prevented from having the disease. As used herein, a “therapeutic effective amount” means a compound or composition sufficient to prevent, treat, inhibit, reduce, alleviate, or eliminate a disease, such as one or more causes, symptoms, or complications of cancer.
[0088] The term "subject" refers to animals including mammals and humans, especially humans.
[0089] The term "prodrug" or its equivalents refer to a reagent that is directly or indirectly converted into its active form in vitro or in vivo. Prodrugs can be used to alter the biodistribution (e.g., preventing the drug from normally entering protease reaction sites) or pharmacokinetics of a specific drug. A variety of groups have been used to modify compounds to form prodrugs, such as esters, ethers, phosphate esters / salts, etc. When a prodrug is administered to a subject, the group is cleaved away enzymatically or non-enzymatically, reducingly, oxidatively, or hydrolyzed, or otherwise releases the active compound. As used herein, "prodrug" includes pharmaceutically acceptable salts, or pharmaceutically acceptable solvates or chelates, and any crystalline form of the compounds described above.
[0090] The term "effective amount" refers to the quantity or dose of a therapeutic agent (e.g., a compound) that, when administered to a subject in a single or multiple doses, provides the desired therapeutic, diagnostic, or prognostic effect in the subject. The effective amount can be readily determined by the attending or diagnostic physician using known techniques and by observing results obtained in similar circumstances. In determining the effective amount or dose of the administered compound, many factors are considered, including but not limited to: the subject's weight, age, and general health condition; the specific disease involved; the extent or severity of the disease or condition to be treated; the individual subject's response; the specific compound administered; the administration method; the bioavailability characteristics of the administered formulation; the chosen dosing regimen; the use of concomitant medications; and other relevant considerations.
[0091] In other embodiments, the present invention provides the use of at least one compound or composition provided by the present invention for the treatment and / or prevention of cGAS-related diseases, disorders and symptoms.
[0092] Other diseases, disorders, and conditions that can be treated or prevented, either wholly or partially, by inhibiting cGAS activity are also candidate indications for the compounds and compositions provided in this invention.
[0093] The term "treatment" refers to the initiation of action (e.g., administration of a cGAS inhibitor or a pharmaceutical composition containing it) after a disease, disorder, or condition or its symptoms have been diagnosed or observed, in order to temporarily or permanently eliminate, reduce, suppress, alleviate, or improve at least one underlying cause of the disease, disorder, or condition afflicting the subject, or symptoms associated with the disease, disorder, or condition afflicting the subject. Therefore, treatment includes suppressing (e.g., preventing or alleviating the development or further development of a disease, disorder, or condition or its associated clinical symptoms) an active disease.
[0094] The term "prevention" refers to initiating action (e.g., administering a cGAS inhibitor or a pharmaceutical composition containing it) in a certain way (e.g., before the onset of a disease, disorder, condition, or its symptoms) to temporarily or permanently prevent, suppress, inhibit, or reduce the risk of a subject having a disease, disorder, or condition (as determined by, for example, the absence of clinical symptoms) or, in the case of a subject susceptible to a particular disease, disorder, or condition, delay its onset. In some cases, the term also refers to slowing the progression of a disease, disorder, or condition or inhibiting its development into a harmful or other undesirable state.
[0095] The term "cGAS-related disease" or other synonymous expressions refer to any disease, condition, or other pathological symptom mediated by cGAS. For example, cGAS-related diseases include, but are not limited to, inflammatory, allergic, or autoimmune diseases such as systemic lupus erythematosus (SLE), cutaneous lupus erythematosus, scleroderma, psoriasis, Eckhart Gutierrez syndrome, Sjögren's syndrome, rheumatoid arthritis, inflammatory bowel disease; multiple sclerosis; diabetes; cardiovascular disease; neurodegenerative diseases; cancers, including but not limited to bladder cancer, bone cancer, brain cancer, breast cancer, gastric cardia cancer, cervical cancer, colon cancer, colorectal cancer, esophageal cancer, fibrosarcoma, gastric cancer, gastrointestinal cancer, head and neck cancer, Kaposi's sarcoma, kidney cancer, pancreatic cancer, penile cancer, testicular germ cell cancer, thymoma, thymic carcinoma, lung cancer, ovarian cancer, and prostate cancer; inflammation, including musculoskeletal inflammation, vascular inflammation, neurological inflammation, digestive system inflammation, eye inflammation, reproductive system inflammation, and other inflammations.
[0096] In some embodiments, the present invention further provides the use of the cGAS-mediated inhibitor compounds and compositions described herein in combination with one or more additional agents. These one or more additional agents may have cGAS-mediated regulatory activity and / or they may act through different mechanisms of action. In some embodiments, such agents, including these additional agents, may include: antigen immunotherapeutic agents; antihistamines; steroids, nonsteroidal anti-inflammatory drugs; bronchodilators (e.g., β2 agonists, adrenergic agonists, anticholinergics, theophylline); monoclonal antibody agents, such as anti-IgE, anti-TNF, anti-IL-5, anti-IL-6, anti-IL-12, anti-IL-1, and similar agents; receptor therapeutic agents, such as enalapril; and antigen nonspecific immunotherapeutic agents, such as interferon or other cytokines / chemokines, cytokine / chemokine receptor modulators, cytokine agonists or antagonists, and TLR antagonists.
[0097] When using combination therapy, the cGAS-mediated inhibitor and another agent can be a single composition or a combination of multiple agents, and the treatment can be administered simultaneously, sequentially, or through other regimens. Combination therapy can have additive or synergistic effects.
[0098] Pharmaceutical compositions containing an active ingredient (e.g., a cGAS inhibitor) can be in forms suitable for oral administration, such as tablets, capsules, lozenges, sugar tablets, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups, solutions, microbeads, or elixirs. Pharmaceutical compositions for oral administration can be prepared according to any method known in the art for manufacturing pharmaceutical compositions, and such compositions can contain one or more agents, such as sweeteners, flavoring agents, coloring agents, and preservatives, to provide a pharmaceutically acceptable formulation. Tablets, capsules, etc., typically contain the active ingredient mixed with a non-toxic, pharmaceutically acceptable carrier or excipient suitable for manufacturing tablets. These carriers or excipients can be, for example, diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, or sodium phosphate; granulating and disintegrants such as corn starch or alginate; binders such as starch, gelatin, or gum arabic; and lubricants such as magnesium stearate, stearic acid, or talc.
[0099] In some embodiments, the composition is an injectable formulation. In other embodiments, the composition is formulated for oral administration to a subject.
[0100] In some embodiments, the pharmaceutical composition is contained in a single-use container (e.g., a single-use vial, ampoule, syringe, or autoinjector), while in other embodiments, it is contained in a reusable container (e.g., a reusable vial).
[0101] The formulation may also include a carrier to protect the composition from rapid degradation or disappearance from the body, such as controlled-release formulations, including liposomes, hydrogels, and microencapsulated delivery systems. For example, delayed-release materials, such as glyceryl monostearate or glyceryl stearate alone, or in combination with waxes, may be used. Any drug delivery device can be used to deliver cGAS inhibitors, including implants (e.g., implantable pumps) and catheter systems, slow-infusion pumps, and devices. All of these are well known to those skilled in the art.
[0102] Pharmaceutical compositions can also be in the form of sterile injectable aqueous or oily suspensions. These suspensions can be formulated using suitable dispersants or wetting agents and suspending agents mentioned in this application, according to known techniques. Sterile injectable formulations can also be sterile injectable solutions or suspensions in non-toxic, parenteral-acceptable diluents or solvents, such as solutions in 1,3-butanediol. Acceptable diluents, solvents, and dispersion media that can be used include water, Ringer's solution, isotonic sodium chloride solution, Cremophor ELTM (BASF, Parsippany, NJ) or phosphate-buffered saline (PBS), alcohols, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. Additionally, sterile fixative oils are commonly used as solvents or suspension media. For this purpose, any mild fixative oil can be used, including synthetic monoglycerides or diglycerides. Furthermore, fatty acids (such as oleic acid) can be used to prepare injectable formulations. Prolonged absorption of specific injectable formulations can be achieved by including agents that delay absorption (e.g., aluminum monostearate or gelatin).
[0103] The cGAS inhibitor compounds and compositions provided by this invention can be administered to subjects in any suitable manner known in the art. Suitable routes of administration include, but are not limited to, oral; parenteral, such as intramuscular, intravenous, subcutaneous (e.g., injection or implantation), intraperitoneal, intracisional, intraarticular, intracranial (within the brain parenchyma and ventricles; nasal; vaginal; sublingual; intraocular; rectal; local (e.g., transdermal); oral and inhalation.
[0104] Example
[0105] The following examples further describe the preparation of the compounds and pharmaceutically acceptable salts described in this disclosure, but these examples are not intended to limit the scope of this disclosure.
[0106] Experimental methods in the embodiments of this disclosure that do not specify specific conditions are generally performed under conventional conditions or as recommended by the raw material or product manufacturer. Reagents whose specific source is not specified are commercially available conventional reagents.
[0107] Example 1: Preparation of Compound 1
[0108]
[0109] Step 1: Add AcOH (1 mL) to a solution of compound 1-1 (5000 mg, 28.244 mmol) and ethyl pyruvate (3279.67 mg, 28.244 mmol) in EtOH (50 mL), and heat under reflux for 2 hours. After the reaction is complete, cool the reaction solution to 20°C, filter the precipitated solid, wash the filter cake with a small amount of EtOH, and then dry under vacuum to obtain compound 1-2 (6800 mg, yield: 87.51%) as a pale yellow solid.
[0110] MS-ESI(m / z):275.0 / 277.0[M+H] + .
[0111] Step 2: Compound 1-2 (5800 mg, 21.081 mmol) was added in portions to Eaton reagent (10 mL) under constant stirring at 20 °C. After the addition was complete, the reaction mixture was heated to 110 °C and stirred for 1 hour. After the reaction was complete, the reaction mixture was added dropwise to ice water (200 mL) under vigorous stirring. After the addition was complete, stirring was continued until a solid powder with uniform particle size was obtained. The mixture was filtered, and the filter cake was washed with water (10 mL x 3). Finally, it was dried under vacuum to obtain compound 1-3 (4800 mg, yield: 88.22%) as a brown solid.
[0112] MS-ESI(m / z):259.0 / 260.0[M+H] + .
[0113] Step 3: Under nitrogen protection, a THF solution of LiAlH4 (22.317 mL, 1 M) was slowly added dropwise to a THF solution of compounds 1-3 (4800 mg, 18.597 mmol) at 0 °C (48 mL). After the addition was complete, the resulting reaction solution was slowly heated to 20 °C and stirred for 12 hours. After the reaction was complete, the reaction solution was quenched by slowly adding H2O (3 mL), and then anhydrous Na2SO4 was added to the reaction solution for drying. The solution was filtered through diatomaceous earth, and the filter cake was washed with DCM / MeOH = 10 / 1 (30 mL x 3). The combined filtrates were concentrated to dryness. The residue was subjected to silica gel column chromatography (PE / EtOAc = 10 / 1) to obtain compounds 1-4 (2650 mg, yield: 65.95%) as a yellow solid.
[0114] MS-ESI(m / z):216.0 / 218.0[M+H] + .
[0115] Step 4: The suspension of compounds 1-4 (2600 mg, 12.034 mmol) and active MnO2 (10462.09 mg, 120.337 mmol) in DCM (200 mL) was stirred at 25 °C for 12 hours. After the reaction was complete, the reaction solution was filtered through diatomaceous earth, the filter cake was washed with DCM (200 mL), and the filtrate was concentrated to dryness to obtain compounds 1-5 (1720 mg, yield: 66.78%) as a brown solid.
[0116] MS-ESI(m / z):214.0 / 216.0[M+H] + .
[0117] Step 5: Under nitrogen protection, compounds 1-5 (1.5 g, 7.01 mmol) and ammonium acetate (1.24 g, 21.03 mmol) were sequentially added to nitromethane (21 mL) at 25 °C. The resulting mixture was heated to 50 °C and stirred for 5 hours. After the reaction was completed by TLC monitoring, excess nitromethane was removed by vacuum distillation. The residue was purified by silica gel column chromatography (PE / EA = 30 / 1) to give compounds 1-6 (780 mg, yield: 42%) as a brown solid.
[0118] 1 H-NMR (400MHz, DMSO-d6) δ12.03(brs,1H),8.40(d,J=13.5Hz,1H),8.18(d,J=13.5Hz,1H),7.67(d,J=8.5Hz,1H),7.36(s,1H),7.29(d,J=8.5Hz,1H).
[0119] Step 6: Under nitrogen protection, triethylamine (476.29 mg, 4.707 mmol) was added to a tetrahydrofuran (44 mL) solution of compounds 1-6 (550 mg, 2.139 mmol), compounds 1-7 (89.69 mg, 0.214 mmol), and anhydrous chloroacetaldehyde (201.54 mg, 2.567 mmol) (extracted from 40% chloroacetaldehyde aqueous solution (10 mL) with dichloromethane (10 mL x 3), the combined extracts were washed with saturated brine (10 mL), dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated and evaporated to dryness at 20 °C to obtain 1.6 g of colorless oily chloroacetaldehyde). The reaction solution was then heated to 50 °C and stirred for 1 hour. After the reaction was completed, the reaction solution was directly purified by reverse phase (C18 reverse phase silica column, mobile phase A: 0.1% formic acid aqueous solution; mobile phase B: methanol; 5%-100% for 30 min; detection wavelength 254 nm / 220 nm), and concentrated to dryness to obtain compounds 1-8 (230 mg, yield: 35.94%) as a reddish-brown solid.
[0120] MS-ESI(m / z):299.0 / 301.0[M+H] + .
[0121] Step 7: Add borane-tetrahydrofuran solution (2 mL, 2.00 mmol, 1 M) to a tetrahydrofuran solution of compounds 1-8 (200 mg, 0.669 mmol). Heat the mixture to 65 °C and stir for 6 hours under nitrogen protection. After the reaction is complete, cool the reaction solution to 0 °C and slowly add methanol (2 mL) dropwise while maintaining the temperature at 0 °C. The mixture of compounds 1-9 can be used directly for the next step of the reaction.
[0122] MS-ESI(m / z):285.0 / 287.0[M+H]+ .
[0123] Step 8: Add nickel chloride hexahydrate (237.58 mg, 1.00 mmol) and sodium borohydride (37.81 mg, 1.00 mmol) to the mixture of compounds 1-9 at 0 °C. Stir the resulting mixture under nitrogen protection at 0 °C for 1 hour. After the reaction is complete, quench the reaction solution with saturated NH4Cl (5 mL), extract with DCM (10 mL x 3), wash the combined extracts with saturated brine (10 mL), dry with anhydrous Na2SO4, filter, and concentrate the filtrate to obtain compounds 1-10 (130 mg, crude product) as a yellow solid, which can be directly used in the next reaction.
[0124] MS-ESI(m / z):255.0 / 257.0[M+H] + .
[0125] Step 9: Under nitrogen protection and at 25°C, acetaldehyde (5.0 M in THF, 0.12 mL, 0.611 mmol) and trifluoroacetic acid (87.14 mg, 0.764 mmol) were added to a THF (2 mL) solution of compound 1-10 (130 mg, crude product). The resulting reaction solution was stirred at this temperature for 1 hour. After the reaction was complete, saturated NaHCO3 aqueous solution (5 mL) was added to the reaction solution, and the mixture was extracted with DCM (10 mL x 3). The combined extracts were washed with saturated brine (10 mL x 2), dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated to dryness. The crude product was purified by reverse-phase chromatography (C18 reverse-phase silica gel column, mobile phase A: 0.1% ammonium bicarbonate aqueous solution; mobile phase B: acetonitrile; 5%-100% for 20 min; detection wavelength 254 nm / 220 nm). The purified product was concentrated to dryness to obtain compound 1-11 (30 mg, three-step yield: 15.96%) as a yellow solid.
[0126] MS-ESI(m / z):281.0 / 283.0[M+H] + .
[0127] Step 10: Add DIEA (13.79 mg, 0.107 mmol) and HATU (17.58 mg, 0.046 mmol) to a DMF (1 mL) mixture of compounds 1-11 (10 mg, 0.036 mmol) and glycolic acid (3.52 mg, 0.046 mmol). Stir the reaction solution at 25 °C under nitrogen protection for 20 minutes. After the reaction is complete, directly purify the reaction solution by reverse phase (C18 reversed-phase silica gel column, mobile phase A: 0.1% ammonium bicarbonate aqueous solution; mobile phase B: acetonitrile; 5%-100% for 20 min; detection wavelength 254 nm / 220 nm). Concentrate to dryness to obtain compound 1 (4.2 mg, yield: 35.64%) as a white solid.
[0128] 1 H-NMR (400MHz, DMSO-d6) δ7.54(d,J=8.0Hz,1H),7.22(d,J=8.2Hz,1H),5.27(q,J=6.2Hz,1H),4.33-4.62(m ,3H),4.05-4.27(m,3H),3.49(q,J=8.2Hz,1H),2.75-2.96(m,2H),2.21-2.40(m,1H),1.53(d,J=6.2Hz,3H).
[0129] MS-ESI(m / z):339.1 / 341.0[M+H] + .
[0130] Compound 1 was chiral analyzed (column: CHIRALART Cellulose-SB 4.6*50mm, 3µm; mobile phase: phase A, supercritical fluid CO2, phase B, MeOH (0.1% DEA); elution gradient (B%): from 10% to 50% over 2 min, then held at 50% for 1 min; flow rate: 4 mL / min; temperature: 35℃; detection wavelength: 220 nm) and the retention time (Rt) was 1.397 min.
[0131] Example 2: Preparation of Compound 2
[0132]
[0133] Step 1: Add DIEA (13.79 mg, 0.107 mmol) and HATU (17.58 mg, 0.046 mmol) to a DMF (1 mL) mixture of compounds 1-11 (10 mg, 0.036 mmol) and 2-1 (13.75 mg, 0.046 mmol). Stir the reaction solution at 25 °C under nitrogen protection for 20 minutes. After the reaction is complete, purify the reaction solution directly by reverse phase (C18 reversed-phase silica gel column, mobile phase A: 0.1% ammonium bicarbonate aqueous solution; mobile phase B: acetonitrile; 5%-100% for 20 min; detection wavelength 254 nm / 220 nm). Concentrate to dryness to obtain compound 2-2 (6 mg, yield: 30.10%) as a white solid.
[0134] MS-ESI(m / z):560.2 / 562.2[M+H] + .
[0135] Step 2: Morpholine (0.3 mL) was added to a DCM (0.6 mL) solution of compound 2-2 (6 mg, 0.011 mmol). The solution was stirred and reacted at 25 °C under nitrogen protection for 4 hours. After the reaction was complete, the DCM in the reaction solution was evaporated to dryness, and the remaining crude product was purified by reverse phase (C18 reverse phase silica gel column, mobile phase A: 0.1% ammonium bicarbonate aqueous solution; mobile phase B: acetonitrile; 5%-100% for 20 min; detection wavelength 254 nm / 220 nm). The purified product was concentrated to dryness to obtain compound 2 (2.02 mg, yield 55.79%) as a yellow solid.
[0136] 1 H-NMR (400MHz, DMSO-d6) δ7.51(d,J=8.4Hz,1H),7.20(d,J=8.4Hz,1H),5.29(dd,J=16.0,9.8Hz,1H),4.33-4.47(m,2H),4.1 4(dd,J=11.6,7.0Hz,1H),3.42-3.58(m,2H),3.35-3.39(m,1H),2.74-2.85(m,2H),2.22-2.32(m,1H),1.48(d,J=6.2Hz,3H).
[0137] MS-ESI(m / z):338.1 / 340.1[M+H] + .
[0138] Example 3: Preparation of Compound 3
[0139]
[0140] Step 1: Add DIEA (24.63 mg, 0.204 mmol) and HATU (31.1 mg, 0.082 mmol) to a DMF (1 mL) mixture of compounds 1-11 (11.5 mg, 0.041 mmol) and 3-1 (3.68 mg, 0.041 mmol). Stir the reaction solution at 25 °C under nitrogen protection for 20 minutes. After the reaction is complete, purify the reaction solution directly by reversed-phase column chromatography (C18 reversed-phase silica gel column, mobile phase A: 0.1% ammonium bicarbonate aqueous solution; mobile phase B: acetonitrile; 5%-100% for 20 min; detection wavelength 254 nm / 220 nm) to obtain compound 3 (1.72 mg, yield: 10.83%) as a brown oily substance.
[0141] 1H-NMR (400MHz, DMSO-d6) δ7.53(d,J=8.4Hz,1H),7.23(d,J=8.4Hz,1H),5.26(q,J=6.2Hz,1H),4.34-4.53(m,2H),4.26(d,J=14.4Hz,1H) ,4.13-4.22(m,1H),4.07(d,J=14.4Hz,1H),3.44-3.52(m,1H),3.33(s,3H),2.75-2.94(m,2H),2.17-2.34(m,1H),1.51(d,J=6.2Hz,3H).
[0142] MS-ESI(m / z):353.1 / 355.1[M+H] + .
[0143] Example 4: Preparation of Compound 4
[0144]
[0145] Step 1: A mixture of compounds 1-6 (400 mg, 1.556 mmol), compound 4-1 (65.23 mg, 0.156 mmol), chloroacetaldehyde (146.57 mg, 1.867 mmol, prepared as above), and triethylamine (314.90 mg, 3.112 mmol) in tetrahydrofuran (40 mL) was heated to 50 °C and stirred for 1 hour under nitrogen protection. After the reaction was complete, the reaction solution was directly purified by reverse phase (C18 reverse phase silica gel column, mobile phase A: 0.1% formic acid aqueous solution; mobile phase B: methanol; 5%-100% for 30 min; detection wavelength 254 nm / 220 nm), and concentrated to dryness to obtain compound 4-2 (240 mg, yield: 51.57%) as a reddish-brown solid.
[0146] MS-ESI(m / z):299.0 / 301.0[M+H] + .
[0147] Step 2: Add borane-tetrahydrofuran solution (2 mL, 2.00 mmol, 1 M) to a tetrahydrofuran solution of compound 4-2 (240 mg, 0.802 mmol). Heat the mixture to 65 °C and stir for 6 hours under nitrogen protection. After the reaction is complete, cool the reaction solution to 0 °C and slowly add methanol (2 mL) dropwise while maintaining the temperature at 0 °C. The mixture of compound 4-3 can be used directly for the next step of the reaction.
[0148] MS-ESI(m / z):285.0 / 287.0[M+H] + .
[0149] Step 3: Nickel chloride hexahydrate (285.10 mg, 1.00 mmol) and sodium borohydride (45.38 mg, 1.00 mmol) were added to the mixture of compounds 4-3 at 0 °C. The resulting mixture was stirred for 1 hour under nitrogen protection at 0 °C. After the reaction was complete, the reaction solution was quenched with saturated NH4Cl (5 mL), extracted with DCM (10 mL x 3), and the combined extracts were washed with saturated brine (10 mL), dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated to dryness to obtain compound 4-4 (180 mg, crude product) as a yellow solid, which was directly used in the next step of the reaction.
[0150] MS-ESI(m / z):255.0 / 257.0[M+H] + .
[0151] Step 4: Under nitrogen protection and at 25°C, acetaldehyde (5.0 M in THF, 0.169 mL, 0.847 mmol) and trifluoroacetic acid (120.66 mg, 1.058 mmol) were added to a THF (2 mL) solution of compound 4-4 (180 mg, crude product). The reaction solution was stirred at this temperature for 1 hour. After the reaction was complete, saturated NaHCO3 aqueous solution (5 mL) was added to the reaction solution, and the mixture was extracted with DCM (10 mL x 3). The combined extracts were washed with saturated brine (10 mL x 2), dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated to dryness. The crude product was purified by reverse-phase purification (C18 reversed-phase silica gel, mobile phase A: 0.1% ammonium bicarbonate aqueous solution; mobile phase B: acetonitrile; 5%-100% for 20 min; detection wavelength 254 nm / 220 nm), and concentrated to dryness to obtain compound 4-5 (40 mg, three-step yield: 17.78%) as a yellow solid.
[0152] MS-ESI(m / z):281.0 / 283.0[M+H] + .
[0153] Step 5: Add DIEA (13.79 mg, 0.107 mmol) and HATU (17.58 mg, 0.046 mmol) to a DMF (1 mL) mixture of compounds 4-5 (10 mg, 0.036 mmol) and glycolic acid (3.52 mg, 0.046 mmol). Stir the reaction solution at 25 °C under nitrogen protection for 20 minutes. After the reaction is complete, purify the reaction solution directly by reverse phase (C18 reverse phase silica gel column, mobile phase A: 0.1% ammonium bicarbonate aqueous solution; mobile phase B: acetonitrile; 5%-100% for 20 min; detection wavelength 254 nm / 220 nm). Concentrate to dryness to obtain compound 4 (3.6 mg, yield: 29.84%) as a yellow solid.
[0154] 1H-NMR (400MHz, DMSO-d6) δ7.51(d,J=8.4Hz,1H),7.20(d,J=8.4Hz,1H),5.25(q,J=6.2Hz,1H),4.32-4.53( m,3H),4.28-3.95(m,3H),3.43-3.51(m,1H),2.74-2.85(m,2H),2.22-2.32(m,1H),1.50(d,J=6.2Hz,3H).
[0155] MS-ESI(m / z):339.1 / 341.0[M+H] + .
[0156] Compound 4 was chirally analyzed (column: CHIRALART Cellulose-SB 4.6*50mm, 3µm; mobile phase: phase A, supercritical fluid CO2, phase B, MeOH (0.1% DEA); elution gradient (B%): from 10% to 50% over 2 min, then held at 50% for 1 min; flow rate: 4 mL / min; temperature: 35℃; detection wavelength: 220 nm) and the retention time (Rt) was 1.609 min.
[0157] Example 5: Preparation of Compound 5
[0158]
[0159] Step 1: Add DIEA (20.69 mg, 0.160 mmol) and HATU (26.37 mg, 0.069 mmol) to a mixed solution of compounds 4-5 (15 mg, 0.053 mmol) and 2-1 (20.62 mg, 0.069 mmol) in DMF (1 mL). Stir the reaction solution at 25 °C under nitrogen protection for 20 minutes. After the reaction is complete, purify the reaction solution directly by reverse phase (C18 reversed-phase silica gel column, mobile phase A: 0.1% ammonium bicarbonate aqueous solution; mobile phase B: acetonitrile; 5%-100% for 20 min; detection wavelength 254 nm / 220 nm). Concentrate to dryness to obtain compound 5-1 (7 mg, yield: 23.41%) as a white solid.
[0160] MS-ESI(m / z):560.2 / 562.2[M+H] + .
[0161] Step 2: Morpholine (0.3 mL) was added to a DCM (0.6 mL) solution of compound 5-1 (6 mg, 0.011 mmol). The solution was stirred and reacted at 25 °C under nitrogen protection for 4 hours. After the reaction was complete, the DCM in the reaction solution was evaporated to dryness, and the remaining crude product was purified by reverse-phase chromatography (C18 reverse-phase silica gel column, mobile phase A: 0.1% ammonium bicarbonate aqueous solution; mobile phase B: acetonitrile; 5%-100% for 20 min; detection wavelength 254 nm / 220 nm). The purified product was concentrated to dryness to obtain compound 5 (2.6 mg, yield 61.55%) as a yellow solid.
[0162] 1 H-NMR (400MHz, DMSO-d6) δ7.50(d,J=8.4Hz,1H),7.20(d,J=8.4Hz,1H),5.26(q,J=6.2Hz,1H),4.31-4.51(m,2H),4.14(d d,J=11.6,6.8Hz,1H),3.42-3.57(m,2H),3.34-3.37(m,1H),2.78-2.85(m,2H),2.22-2.32(m,1H),1.48(d,J=6.2Hz,3H).
[0163] MS-ESI(m / z):338.1 / 340.1[M+H] + .
[0164] Example 6: Preparation of Compound 6
[0165]
[0166] Step 1: Add DIEA (13.79 mg, 0.107 mmol) and HATU (17.58 mg, 0.046 mmol) to a mixed solution of compounds 4-5 (10 mg, 0.036 mmol) and 3-1 (4.16 mg, 0.046 mmol) in DMF (1 mL). Stir the reaction solution at 25 °C under nitrogen protection for 20 minutes. After the reaction is complete, directly purify the reaction solution by reverse phase (C18 reverse phase silica gel column, mobile phase A: 0.1% ammonium bicarbonate aqueous solution; mobile phase B: acetonitrile; 5%-100% for 20 min; detection wavelength 254 nm / 220 nm) to obtain compound 6 (2.9 mg, yield: 23.08%) as a brown oily substance.
[0167] 1H-NMR (400MHz, DMSO-d6) δ7.53(d,J=8.4Hz,1H),7.23(d,J=8.4Hz,1H),5.26(q,J=6.2Hz,1H),4.34-4.53(m,2H),4.26(d,J=14.4Hz,1H),4.17 (dd,J=11.6,6.8Hz,1H),4.07(d,J=14.4Hz,1H),3.44-3.52(m,1H),3.33(s,3H),2.75-2.94(m,2H),2.17-2.34(m,1H),1.51(d,J=6.2Hz,3H).
[0168] MS-ESI(m / z):353.1 / 355.1[M+H] + .
[0169] Test case
[0170] 1. hcGAS fluorescence polarization biochemical experiment
[0171] 1) Materials and Instruments
[0172]
[0173]
[0174] 2) Standard reagent formulation
[0175] 1× Detection buffer (prepared with ddH2O) (pH=7.5)
[0176] reagents Storage concentration Final concentration TRIS 1000mM 20mM <![CDATA[MgCl2]]> 1000mM 5mM Brij-35 10% 0.01%
[0177] 5 μL enzyme and DNA mixture
[0178] reagents Storage concentration 2× concentration Final concentration Human-derived cGAS 14.5μM 60nM 30nM Double-stranded DNA (dsDNA) 25μM 8nM 4nM 1× Detection Buffer
[0179] 5 μL ATP and GTP mixture
[0180] reagents Storage concentration 2× concentration Final concentration ATP 5mM 200μM 100μM GTP 5mM 200μM 100μM 1× Detection Buffer
[0181] 10 μL cGAMP detection mixture
[0182] reagents Storage concentration Final concentration cGAMP Antibody 1.8 mg / mL 1.0 μg / mL cGAMP ATTO 633Tracer 800nM 4nM Stop & Detect Buffer B 10X 1X water
[0183] 3) Experimental steps
[0184] 1. Dilute the compound to different concentrations using DMSO in 384 plates.
[0185] 2. Use the Echo dispensing system to transfer 100 nL of DMSO or the compound to a 384-well detection plate. Note: G150 is used as a reference compound, and the final working concentration is set as follows: starting concentration of 10000 nM, serially diluted 3 times.
[0186] 3. Add 5 μL (2x concentration) of human cGAS enzyme and DNA mixture to the detection plate and incubate at room temperature (RT) for 60 minutes (see table above).
[0187] 4. Add 5 μL (2 times concentration) of ATP and GTP mixture to start the reaction and incubate at room temperature for 120 minutes (see table above).
[0188] 5. Add 10 μL of detection reagent and incubate at room temperature for 60 minutes.
[0189] 6. Use a Pherastar microplate reader to read the fluorescence polarization value (mP).
[0190] 4. Data Analysis
[0191] 1. The stability of the detection experiment was evaluated using data from DMSO and 10000nM G150 groups (positive and negative controls, respectively):
[0192] ΔmP=ave G150-ave DMSO
[0193] Z'=1-3*(SD DMSO+SD ref) / (ave DMSO-ave ref)
[0194] Inhibition%:(cpds-ave G150) / (ave G150-ave DMSO)*100
[0195] 2. Fitting the IC50 value of the compound using a nonlinear regression equation:
[0196] Y=Bottom+(Top-Bottom) / (1+10^((LogIC50-X)*Hillslope))
[0197] Parameter Description
[0198] X: Logarithm of compound concentration
[0199] Y: Inhibition percentage (%inh)
[0200] Maximum value and baseline: Y-axis plateau value (unit consistent with Y).
[0201] LogIC50: The same logarithmic unit as X.
[0202] Hillslope: Hill slope factor
[0203] 4) Experimental Results
[0204]
[0205]
[0206] 2. ISG-luc experiment
[0207] THP1-ISG-luc2p cells were cultured in RPMI-1640 medium containing 10% fetal bovine serum (FBS), 2 mM L-glutamine, and 1% penicillin-streptomycin. The cells were cultured at a density of 2 × 10⁶ cells per well. 4 Cells were seeded at a density of [number] cells per well in 96-well plates. Gradual concentrations of the compound (DMSO < 0.5%) were added for 24 hours. Subsequently, pcDNA3.1 plasmid was transfected with Lipofectamine 3000 (final concentration 0.3 μg / mL) for 24 hours. After 24 hours of treatment, luciferase activity was detected using the Bright-Glo luciferase reporter system, and curve fitting was performed using GraphPad Prism software.
[0208] Experimental results:
[0209] Compound numbering THP1-ISG-luc2p IC50 Example 1 46nM Example 2 174nM Example 3 474nM Example 4 3.223μM Example 5 10.1μM Example 6 8.008μM
[0210] It should be understood that the above embodiments are exemplary and are not intended to encompass all possible implementations included in the claims. Various modifications and changes can be made to the above embodiments without departing from the scope of this disclosure. Similarly, the various technical features of the above embodiments can be arbitrarily combined to form other embodiments of the present invention that may not be explicitly described. Therefore, the above embodiments only illustrate several implementations of the present invention and do not limit the scope of protection of this patent.
Claims
1. The compound represented by Formula I, or a pharmaceutically acceptable stereoisomer, solvate, hydrate, prodrug, stable isotopic derivative, or salt thereof: in, R1, R2, R3, and R5 are each independently selected from hydrogen, halogen, cyano, hydroxyl, amino, alkyl, alkoxy, haloalkyl, and cycloalkyl. R4 is selected from hydrogen, alkyl, alkoxy, haloalkyl, cycloalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic; wherein when the heteroaryl, aryl and heterocyclic are substituted, the substituent is selected from halogen, amino, cyano, C1-C4 alkyl and C1-C4 alkoxy. R6 is selected from -CH2-Ra, substituted or unsubstituted heteroaryl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group; wherein when the heteroaryl, aryl and heterocyclic group are substituted, the substituent is selected from halogen, amino, cyano, alkyl, alkoxy, haloalkyl, cycloalkyl, -O(CH2). p OH; p is 1, 2 or 3; Ra is selected from cyano, hydroxyl, amino, alkyl and alkoxy groups; n is 0, 1, or 2; and m can be 0, 1, or 2.
2. The compound according to claim 1, wherein, The compound has the structure shown in Formula Ia: Among them, R1, R2, R3, and R5 are each independently selected from hydrogen, halogen, cyano, hydroxyl, amino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, and C3-C6 cycloalkyl. R4 is selected from hydrogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C3-C6 cycloalkyl, substituted or unsubstituted 5-8-membered heteroaryl, substituted or unsubstituted 6-8-membered aryl, substituted or unsubstituted 4-8-membered heterocyclic group; wherein when the heteroaryl, aryl and heterocyclic group are substituted, the substituent is selected from halogen, amino, cyano, C1-C4 alkyl and C1-C4 alkoxy; R6 is selected from -CH2-Ra, substituted or unsubstituted 5-8-membered heteroaryl, substituted or unsubstituted 6-8-membered aryl, substituted or unsubstituted 4-8-membered heterocyclic group; wherein when the heteroaryl, aryl and heterocyclic group are substituted, the substituent is selected from halogen, amino, cyano, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C3-C6 cycloalkyl, -O(CH2)pOH; p is 1, 2 or 3; Ra is selected from cyano, hydroxyl, amino, C1-C4 alkyl, C1-C4 alkoxy.
3. The compound according to claim 1, wherein, The compound has the structure shown in Formula Ib: Among them, R1, R2, R3, and R5 are each independently selected from hydrogen, halogen, cyano, hydroxyl, amino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, and C3-C6 cycloalkyl. R4 is selected from hydrogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C3-C6 cycloalkyl, substituted or unsubstituted 5-8-membered heteroaryl, substituted or unsubstituted 6-8-membered aryl, substituted or unsubstituted 4-8-membered heterocyclic group; wherein when the heteroaryl, aryl and heterocyclic group are substituted, the substituent is selected from halogen, amino, cyano, C1-C4 alkyl and C1-C4 alkoxy; R6 is selected from -CH2-Ra, substituted or unsubstituted 5-8-membered heteroaryl, substituted or unsubstituted 6-8-membered aryl, substituted or unsubstituted 4-8-membered heterocyclic group; wherein when the heteroaryl, aryl and heterocyclic group are substituted, the substituent is selected from halogen, amino, cyano, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C3-C6 cycloalkyl, -O(CH2)pOH; p is 1, 2 or 3; Ra is selected from cyano, hydroxyl, amino, C1-C4 alkyl, C1-C4 alkoxy.
4. The compound according to claim 1, wherein, The compound has the structure shown in formula Ic: Among them, R1, R2, R3, and R5 are each independently selected from hydrogen, halogen, cyano, hydroxyl, amino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, and C3-C6 cycloalkyl. R4 is selected from hydrogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C3-C6 cycloalkyl, substituted or unsubstituted 5-8-membered heteroaryl, substituted or unsubstituted 6-8-membered aryl, substituted or unsubstituted 4-8-membered heterocyclic group; wherein when the heteroaryl, aryl and heterocyclic group are substituted, the substituent is selected from halogen, amino, cyano, C1-C4 alkyl and C1-C4 alkoxy; R6 is selected from -CH2-Ra, substituted or unsubstituted 5-8-membered heteroaryl, substituted or unsubstituted 6-8-membered aryl, substituted or unsubstituted 4-8-membered heterocyclic group; wherein when the heteroaryl, aryl and heterocyclic group are substituted, the substituent is selected from halogen, amino, cyano, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C3-C6 cycloalkyl, -O(CH2)pOH; p is 1, 2 or 3; Ra is selected from cyano, hydroxyl, amino, C1-C4 alkyl, C1-C4 alkoxy.
5. The compound according to claim 1, wherein, The compound has the structure shown in formula Id: Among them, R1, R2, R3, and R5 are each independently selected from hydrogen, halogen, cyano, hydroxyl, amino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, and C3-C6 cycloalkyl. R4 is selected from hydrogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C3-C6 cycloalkyl, substituted or unsubstituted 5-8-membered heteroaryl, substituted or unsubstituted 6-8-membered aryl, substituted or unsubstituted 4-8-membered heterocyclic group; wherein when the heteroaryl, aryl and heterocyclic group are substituted, the substituent is selected from halogen, amino, cyano, C1-C4 alkyl and C1-C4 alkoxy; R6 is selected from -CH2-Ra, substituted or unsubstituted 5-8-membered heteroaryl, substituted or unsubstituted 6-8-membered aryl, substituted or unsubstituted 4-8-membered heterocyclic group; wherein when the heteroaryl, aryl and heterocyclic group are substituted, the substituent is selected from halogen, amino, cyano, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C3-C6 cycloalkyl, -O(CH2)pOH; p is 1, 2 or 3; Ra is selected from cyano, hydroxyl, amino, C1-C4 alkyl, C1-C4 alkoxy.
6. The compound according to claim 1, wherein, The compound has the structure shown in formula Ie: Among them, R1, R2, R3, and R5 are each independently selected from hydrogen, halogen, cyano, hydroxyl, amino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, and C3-C6 cycloalkyl. R4 is selected from hydrogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C3-C6 cycloalkyl, substituted or unsubstituted 5-8-membered heteroaryl, substituted or unsubstituted 6-8-membered aryl, substituted or unsubstituted 4-8-membered heterocyclic group; wherein when the heteroaryl, aryl and heterocyclic group are substituted, the substituent is selected from halogen, amino, cyano, C1-C4 alkyl and C1-C4 alkoxy; R6 is selected from -CH2-Ra, substituted or unsubstituted 5-8-membered heteroaryl, substituted or unsubstituted 6-8-membered aryl, substituted or unsubstituted 4-8-membered heterocyclic group; wherein when the heteroaryl, aryl and heterocyclic group are substituted, the substituent is selected from halogen, amino, cyano, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C3-C6 cycloalkyl, -O(CH2)pOH; p is 1, 2 or 3; Ra is selected from cyano, hydroxyl, amino, C1-C4 alkyl, C1-C4 alkoxy.
7. The compound according to claim 1, wherein, The compound has the structure shown in Formula If: Among them, R1, R2, R3, and R5 are each independently selected from hydrogen, halogen, cyano, hydroxyl, amino, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, and C3-C6 cycloalkyl. R4 is selected from hydrogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C3-C6 cycloalkyl, substituted or unsubstituted 5-8-membered heteroaryl, substituted or unsubstituted 6-8-membered aryl, substituted or unsubstituted 4-8-membered heterocyclic group; wherein when the heteroaryl, aryl and heterocyclic group are substituted, the substituent is selected from halogen, amino, cyano, C1-C4 alkyl and C1-C4 alkoxy; R6 is selected from -CH2-Ra, substituted or unsubstituted 5-8-membered heteroaryl, substituted or unsubstituted 6-8-membered aryl, substituted or unsubstituted 4-8-membered heterocyclic group; wherein when the heteroaryl, aryl and heterocyclic group are substituted, the substituent is selected from halogen, amino, cyano, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C3-C6 cycloalkyl, -O(CH2)pOH; p is 1, 2 or 3; Ra is selected from cyano, hydroxyl, amino, C1-C4 alkyl, C1-C4 alkoxy.
8. The compound according to any one of claims 2 to 7, wherein, R1, R2, R3, and R5 are each independently selected from hydrogen, halogens, and C1-C4 alkyl groups; R4 is selected from hydrogen, substituted or unsubstituted 5-8 membered heteroaryl groups; wherein when the heteroaryl group is substituted, the substituent is selected from amino or C1-C4 alkyl groups; R6 is selected from -CH2-Ra, or substituted or unsubstituted 5-8 membered heteroaryl groups; wherein when the heteroaryl group is substituted, the substituent is selected from C1-C4 alkoxy or -O(CH2)pOH; p is 1, 2 or 3; Ra is selected from hydroxyl, amino or C1-C4 alkoxy.
9. The compound according to any one of claims 2 to 8, wherein, R1 and R2 are independently selected from halogens, especially chlorine; R3 and R5 are each independently selected from hydrogen or C1-C4 alkyl (e.g., methyl); R4 is selected from hydrogen, substituted or unsubstituted 5-6 membered heteroaryl (e.g. pyrazolyl or pyridinyl); wherein when the heteroaryl is substituted, the substituent is selected from amino or C1-C4 alkyl (e.g. methyl); R6 is selected from -CH2-Ra, or a substituted or unsubstituted 6-membered heteroaryl group (e.g., pyrimidinyl); wherein when the heteroaryl group is substituted, the substituent is selected from C1-C4 alkoxy or -O(CH2)2OH; Ra is selected from hydroxyl, amino or C1-C4 alkoxy (e.g., methoxy).
10. Selected from the following compounds, or pharmaceutically acceptable stereoisomers, solvates, hydrates, prodrugs, stable isotope derivatives, and salts:
11. A small molecule antibody-drug conjugate based on the compound of any one of claims 1 to 10.
12. A small molecule-peptide conjugate based on the compound of any one of claims 1 to 10.
13. A bifunctional protein degrader or other bifunctional small molecule drug based on the compound of any one of claims 1 to 10.
14. A pharmaceutical composition comprising the compound of any one of claims 1 to 10 or a pharmaceutically acceptable stereoisomer thereof, a solvate, a hydrate, a prodrug, a stable isotope derivative and a salt thereof, or a small molecule-antibody conjugate of claim 11, or a small molecule-peptide conjugate of claim 12, or a bifunctional protein degrader or other bifunctional small molecule drug of claim 13; and a pharmaceutically acceptable carrier.
15. Use of the compound according to any one of claims 1 to 10, the small molecule-antibody conjugate according to claim 11, the small molecule-peptide conjugate according to claim 12, the bifunctional protein degrader or other bifunctional small molecule drug according to claim 13, or the pharmaceutical composition according to claim 14 in the preparation of a medicament for the prevention and / or treatment of cGAS-related diseases.
16. The use according to claim 15, wherein, The cGAS-related diseases include inflammation, autoimmune diseases, cancer, infection, central nervous system diseases or disorders, metabolic diseases, cardiovascular diseases, respiratory diseases, kidney diseases, liver diseases, eye diseases, skin diseases, lymphatic diseases, rheumatic diseases, graft-versus-host disease, and abnormal pain.
